# Letter to the Editor



# A novel virtual hospital at home model during the coronavirus disease 2019 (COVID-19) pandemic

Patrick P. Ryan MD, MPH<sup>1,2</sup> <sup>(D)</sup>, Kellie L. Hawkins MD<sup>2,3</sup>, Stacey Altman RN<sup>4</sup>, Lisa Granatowski RN<sup>4</sup>, Bradley D. Shy MD<sup>2,5</sup>, Jeremy Long MD, MPH<sup>1,2</sup> and Rebecca Hanratty MD<sup>1,2</sup>

<sup>1</sup>Department of General Internal Medicine, Denver Health & Hospital Authority, Denver, Colorado, <sup>2</sup>University of Colorado School of Medicine, Aurora, Colorado, <sup>3</sup>Division of Infectious Disease, Department of Medicine, Denver Health & Hospital Authority, Denver, Colorado, <sup>4</sup>Ambulatory Care Services, Community Health Services, Denver Health & Hospital Authority, Denver, Colorado and <sup>5</sup>Department of Emergency Medicine, Denver Health & Hospital Authority, Denver, Colorado

The COVID-19 pandemic has prompted healthcare systems to rapidly adapt healthcare delivery to accommodate a novel infectious disease while considering infection control practices, hospital capacity, and continued management of other medical conditions. Additionally, the COVID-19 pandemic has disproportionately affected minority communities and those suffering from lower socioeconomic status in the United States; populations that already face worse outcomes in other chronic medical conditions such as hypertension, coronary artery disease, and diabetes.<sup>1–3</sup>

To prepare for possible surge capacity, we built a virtual hospital at home (VHH) to manage patients if the hospital could no longer accommodate new admissions. However, in response to early experiences with patients discharged from the emergency department (ED) who later decompensated, we pivoted to provide care to high-risk patients who did not meet the admission criteria.

In this report, we describe the development and implementation of a VHH program at an urban safety-net healthcare system to provide remote monitoring for high risk patients with COVID-19 and the early outcomes associated with this program.

# Methods

#### **Objectives**

The VHH was implemented to provide a safe home monitoring program for COVID-19 patients that did not meet admission criteria to provide an overflow contingency plan if our hospital reached capacity. Secondary goals included analyzing patient outcomes, and assessing the feasibility and acceptability of the VHH in a safety-net system.

### Setting and patient population

Denver Health is an integrated, safety-net healthcare system. Most patients have government insurance (54% Medicaid) or are uninsured (18%). More than half of patients are members of racial/ethnic minority groups: 37% are Hispanic and 14% are black.

#### Virtual hospital at home design

Patients eligible for VHH monitoring include suspected or confirmed COVID-19 cases and at least 1 risk factor for disease complications but do not meet admission criteria (Fig. 1).<sup>1</sup> VHH patients are provided a pulse oximeter and an automated blood pressure cuff to complete home monitoring assessments. VHH patients receive 2 phone calls per day: one from an RN and another from a provider to assess for interval symptom progression. VHH providers represent outpatient attending physicians, resident physicians, and advanced practice providers (ie, nurse practitioners and physician assistants).

Patients demonstrating clinical deterioration are transferred to the nearest ED via a coordinated effort between the VHH program and local EMS. Patients remaining clinically stable and meeting discharge criteria from the VHH are scheduled with their primary care provider (PCP) or receive assistance to establish care if they do not have a PCP.

This project was approved by the institutional quality improvement review committee.

#### Results

In total, 233 patients were referred to VHH for home monitoring between April 3 and May 24, 2020. The mean patient age was 49 years, and the most common risk factors for decompensation were hypertension, obesity, and diabetes (Table 1).

The average duration of VHH monitoring was 4 days. Of enrolled patients, 190 were successfully discharged from the program, 31 (13.3%) required an escalated level of care, and 11 (35.4%) required admission (Table 1). The VHH was unable to contact 13 patients (5.6%). Most patients were uninsured (28.3%) or were covered by Colorado Medicaid (38.2%).

## Discussion

The VHH provided a safe and effective mechanism to remotely monitor a population that has been disproportionately affected by the COVID-19 pandemic. As 95% of patients referred participated, it seemed to be well received by patients, and the program successfully managed most patients within their own homes. Additionally, home-monitoring equipment was well received by patients referred to the VHH, and these tools helped care providers assess the need for care escalations.

© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Author for correspondence: Dr Patrick P. Ryan, E-mail: patrick.ryan@dhha.org

Cite this article: Ryan PP, et al. (2020). A novel virtual hospital at home model during the coronavirus disease 2019 (COVID-19) pandemic. Infection Control & Hospital Epidemiology, https://doi.org/10.1017/ice.2020.435




Fig. 1. Flow Diagram of Virtual Hospital at Home Design and Protocol.

The VHH also assisted in managing hospital capacities through 2 distinct routes. First, the VHH allowed ED providers a mechanism to refer patients to the home-monitoring program who may have otherwise been admitted to an observation inpatient stay, avoiding an influx of admissions for lower acuity patients. Second, the VHH provides hospitalists an outlet to safely discharge COVID-19 patients earlier, knowing that patients will have close outpatient oversight and guidance in their care.

 Table 1. Patient Demographics and Outcomes

CharacteristicOverall No. (%)Age, mean y (SD) $49.2$ (14.7)≥65 $34$ (14.6)Male $108$ (46.4)Does not have PCP $53$ (22.8)COVID-19 Status $COVID-19$ StatusConfirmed $129$ (55.4)Negative $72$ (30.9)Test Unavailable $32$ (13.7)Race/Ethnicity $Y$ White $55$ (23.6)Black $22$ (9.4)Hispanic $145$ (62.2)Other $11$ (4.7)Comorbid conditions $0$ (25.8)Coronary artery disease $9$ (3.9)Chronic heart failure $7$ (3)End-stage renal disease $2$ (0.9)Hyoertrension $142$ (60.9)Cirrhosis $4$ (1.7)Asthma/COPD $54$ (23.2)BMI >30 $96$ (41.2)Malignancy $6$ (2.6)Immunosuppressed $23$ (9.9)Referral source $20$ (34.3)Urgent care $57$ (24.5)
≥65 $34 (14.6)$ Male $108 (46.4)$ Does not have PCP $53 (22.8)$ COVID-19 Status $129 (55.4)$ Negative $72 (30.9)$ Test Unavailable $32 (13.7)$ Race/Ethnicity $145 (62.2)$ White $55 (23.6)$ Black $22 (9.4)$ Hispanic $145 (62.2)$ Other $11 (4.7)$ Comorbid conditions $00 (25.8)$ Diabetes mellitis $60 (25.8)$ Coronary artery disease $9 (3.9)$ Chronic heart failure $7 (3)$ End-stage renal disease $2 (0.9)$ Hyoertrension $142 (60.9)$ Cirrhosis $4 (1.7)$ Asthma/COPD $54 (23.2)$ BMI >30 $96 (41.2)$ Malignancy $6 (2.6)$ Immunosuppressed $23 (9.9)$ Referral source $80 (34.3)$
Male         108 (46.4)           Does not have PCP         53 (22.8)           COVID-19 Status         129 (55.4)           Negative         72 (30.9)           Test Unavailable         32 (13.7)           Race/Ethnicity         145 (62.2)           White         55 (23.6)           Black         22 (9.4)           Hispanic         145 (62.2)           Other         11 (4.7)           Comorbid conditions         111 (4.7)           Diabetes mellitis         60 (25.8)           Coronary artery disease         9 (3.9)           Chronic heart failure         7 (3)           End-stage renal disease         2 (0.9)           Hyoertrension         142 (60.9)           Cirrhosis         4 (1.7)           Asthma/COPD         54 (23.2)           BMI >30         96 (41.2)           Malignancy         6 (2.6)           Immunosuppressed         23 (9.9)           Referral source         23 (9.9)
Does not have PCP53 (22.8)COVID-19 Status129 (55.4)Negative72 (30.9)Test Unavailable32 (13.7)Race/Ethnicity $32$ (13.7)White55 (23.6)Black22 (9.4)Hispanic145 (62.2)Other11 (4.7)Comorbid conditions $9$ (3.9)Diabetes mellitis60 (25.8)Coronary artery disease9 (3.9)Chronic heart failure7 (3)End-stage renal disease2 (0.9)Hyoertrension142 (60.9)Cirrhosis4 (1.7)Asthma/COPD54 (23.2)BMI >3096 (41.2)Malignancy6 (2.6)Immunosuppressed23 (9.9)Referral source23 (9.9)Emergency department80 (34.3)
COVID-19 Status           Confirmed         129 (55.4)           Negative         72 (30.9)           Test Unavailable         32 (13.7)           Race/Ethnicity         32 (13.7)           White         55 (23.6)           Black         22 (9.4)           Hispanic         145 (62.2)           Other         11 (4.7)           Comorbid conditions         50 (25.8)           Diabetes mellitis         60 (25.8)           Coronary artery disease         9 (3.9)           Chronic heart failure         7 (3)           End-stage renal disease         2 (0.9)           Hyoertrension         142 (60.9)           Cirrhosis         4 (1.7)           Asthma/COPD         54 (23.2)           BMI >30         96 (41.2)           Malignancy         6 (2.6)           Immunosuppressed         23 (9.9)           Referral source         23 (9.9)
Confirmed         129 (55.4)           Negative         72 (30.9)           Test Unavailable         32 (13.7)           Race/Ethnicity            White         55 (23.6)           Black         22 (9.4)           Hispanic         145 (62.2)           Other         11 (4.7)           Comorbid conditions            Diabetes mellitis         60 (25.8)           Coronary artery disease         9 (3.9)           Chronic heart failure         7 (3)           End-stage renal disease         2 (0.9)           Hyoertrension         142 (60.9)           Cirrhosis         4 (1.7)           Asthma/COPD         54 (23.2)           BMI >30         96 (41.2)           Malignancy         6 (2.6)           Immunosuppressed         23 (9.9)           Referral source         23 (9.9)
Negative         72 (30.9)           Test Unavailable         32 (13.7)           Race/Ethnicity            White         55 (23.6)           Black         22 (9.4)           Hispanic         145 (62.2)           Other         11 (4.7)           Comorbid conditions            Diabetes mellitis         60 (25.8)           Coronary artery disease         9 (3.9)           Chronic heart failure         7 (3)           End-stage renal disease         2 (0.9)           Hyoertrension         142 (60.9)           Cirrhosis         4 (1.7)           Asthma/COPD         54 (23.2)           BMI >30         96 (41.2)           Malignancy         6 (2.6)           Immunosuppressed         23 (9.9)           Referral source         23 (9.9)
Test Unavailable         32 (13.7)           Race/Ethnicity
Race/Ethnicity           White         55 (23.6)           Black         22 (9.4)           Hispanic         145 (62.2)           Other         11 (4.7)           Comorbid conditions         0           Diabetes mellitis         60 (25.8)           Coronary artery disease         9 (3.9)           Chronic heart failure         7 (3)           End-stage renal disease         2 (0.9)           Hyoertrension         142 (60.9)           Cirrhosis         4 (1.7)           Asthma/COPD         54 (23.2)           BMI >30         96 (41.2)           Malignancy         6 (2.6)           Immunosuppressed         23 (9.9)           Referral source         23 (9.9)
White         55 (23.6)           Black         22 (9.4)           Hispanic         145 (62.2)           Other         11 (4.7)           Comorbid conditions         11 (4.7)           Diabetes mellitis         60 (25.8)           Coronary artery disease         9 (3.9)           Chronic heart failure         7 (3)           End-stage renal disease         2 (0.9)           Hyoertrension         142 (60.9)           Cirrhosis         4 (1.7)           Asthma/COPD         54 (23.2)           BMI >30         96 (41.2)           Malignancy         6 (2.6)           Immunosuppressed         23 (9.9)           Referral source         23 (9.9)
Black       22 (9.4)         Hispanic       145 (62.2)         Other       11 (4.7)         Comorbid conditions       50 (25.8)         Diabetes mellitis       60 (25.8)         Coronary artery disease       9 (3.9)         Chronic heart failure       7 (3)         End-stage renal disease       2 (0.9)         Hyoertrension       142 (60.9)         Cirrhosis       4 (1.7)         Asthma/COPD       54 (23.2)         BMI >30       96 (41.2)         Malignancy       6 (2.6)         Immunosuppressed       23 (9.9)         Referral source       23 (9.3)         Emergency department       80 (34.3)
Hispanic       145 (62.2)         Other       11 (4.7)         Comorbid conditions          Diabetes mellitis       60 (25.8)         Coronary artery disease       9 (3.9)         Chronic heart failure       7 (3)         End-stage renal disease       2 (0.9)         Hyoertrension       142 (60.9)         Cirrhosis       4 (1.7)         Asthma/COPD       54 (23.2)         BMI >30       96 (41.2)         Malignancy       6 (2.6)         Immunosuppressed       23 (9.9)         Referral source       23 (9.3)         Emergency department       80 (34.3)
Other11 (4.7)Comorbid conditions $(4.7)$ Diabetes mellitis $60$ (25.8)Coronary artery disease $9$ (3.9)Chronic heart failure $7$ (3)End-stage renal disease $2$ (0.9)Hyoertrension $142$ (60.9)Cirrhosis $4$ (1.7)Asthma/COPD $54$ (23.2)BMI >30 $96$ (41.2)Malignancy $6$ (2.6)Immunosuppressed $23$ (9.9)Referral source $80$ (34.3)
Comorbid conditionsDiabetes mellitis60 (25.8)Coronary artery disease9 (3.9)Chronic heart failure7 (3)End-stage renal disease2 (0.9)Hyoertrension142 (60.9)Cirrhosis4 (1.7)Asthma/COPD54 (23.2)BMI >3096 (41.2)Malignancy6 (2.6)Immunosuppressed23 (9.9)Referral source80 (34.3)
Diabetes mellitis         60 (25.8)           Coronary artery disease         9 (3.9)           Chronic heart failure         7 (3)           End-stage renal disease         2 (0.9)           Hyoertrension         142 (60.9)           Cirrhosis         4 (1.7)           Asthma/COPD         54 (23.2)           BMI >30         96 (41.2)           Malignancy         6 (2.6)           Immunosuppressed         23 (9.9)           Referral source         Emergency department
Coronary artery disease9 (3.9)Chronic heart failure7 (3)End-stage renal disease2 (0.9)Hyoertrension142 (60.9)Cirrhosis4 (1.7)Asthma/COPD54 (23.2)BMI >3096 (41.2)Malignancy6 (2.6)Immunosuppressed23 (9.9)Referral source80 (34.3)
Chronic heart failure         7 (3)           End-stage renal disease         2 (0.9)           Hyoertrension         142 (60.9)           Cirrhosis         4 (1.7)           Asthma/COPD         54 (23.2)           BMI >30         96 (41.2)           Malignancy         6 (2.6)           Immunosuppressed         23 (9.9)           Referral source         20 (34.3)
End-stage renal disease       2 (0.9)         Hyoertrension       142 (60.9)         Cirrhosis       4 (1.7)         Asthma/COPD       54 (23.2)         BMI >30       96 (41.2)         Malignancy       6 (2.6)         Immunosuppressed       23 (9.9)         Referral source       20 (34.3)
Hyoertrension         142 (60.9)           Cirrhosis         4 (1.7)           Asthma/COPD         54 (23.2)           BMI >30         96 (41.2)           Malignancy         6 (2.6)           Immunosuppressed         23 (9.9)           Referral source         Emergency department
Cirrhosis         4 (1.7)           Asthma/COPD         54 (23.2)           BMI >30         96 (41.2)           Malignancy         6 (2.6)           Immunosuppressed         23 (9.9)           Referral source         2           Emergency department         80 (34.3)
Asthma/COPD         54 (23.2)           BMI >30         96 (41.2)           Malignancy         6 (2.6)           Immunosuppressed         23 (9.9)           Referral source         2           Emergency department         80 (34.3)
BMI >30         96 (41.2)           Malignancy         6 (2.6)           Immunosuppressed         23 (9.9)           Referral source         23           Emergency department         80 (34.3)
Malignancy       6 (2.6)         Immunosuppressed       23 (9.9)         Referral source       23         Emergency department       80 (34.3)
Immunosuppressed23 (9.9)Referral sourceEmergency department80 (34.3)
Referral source       Emergency department     80 (34.3)
Emergency department 80 (34.3)
Ambulatory testing 54 (23.2)
Hospitalist service 36 (15.5)
Other 6 (2.6)
Preferred patient language
English 131 (56.2)
Spanish 94 (40.3)
Non-English/Non-Spanish 8 (3.4)
VHH outcomes
Mean Duration of VHH Monitoring, d (SD) 4.1 (3.1)
Discharged from VHH 190 (81.6)
ED visit 19 (8.2)
Hospital admission 9 (3.9)
ICU admission 2 (0.9)
Unable to contact 13 (5.6)
Insurance coverage
Commercial 37 (15.9)
Medicaid         89 (38.2)
(Continu

Table 1. (Continued)

Characteristic	Overall No. (%)
Medicare	34 (14.6)
Uninsured	66 (28.3)
Unknown/Other	7 (3)

Note. SD, standard deviation; PCP, primary care provider; COPD, chronic obstructive pulmonary disease; BMI, body mass index; VHH, virtual hospital at home; ICU, intensive care unit.

Although prior hospital-at-home programs have used home visits as the care delivery mechanism, the VHH built upon these constructs exclusively through telehealth, while demonstrating program feasibility and safe patient care.<sup>4,5</sup> By exclusively utilizing a telehealth approach, the VHH minimized the impact on inpatient PPE supplies during the COVID-19 pandemic.

Furthermore, this project demonstrates the acceptance of a novel telehealth program among a diverse patient population, most of whom were ethnic minorities and were either uninsured or relied on some form of government insurance. As the COVID-19 pandemic has disproportionately affected ethnic minority groups, more widespread implementation of telehealth home monitoring programs may even out this health disparity, but further study is needed to address this particular question.

Lastly, the VHH provides an opportunity to connect patients to longitudinal primary care. The VHH assisted unestablished patients to connect with enrollment services to implement medical coverage options, and it helped give patients direct access to scheduling in primary care clinics.

This evaluation has limitations. The program was designed to be a clinical intervention, not a prospective study, and our study cohort did not have a comparison group. Only patients with a functioning phone number could participate. The results are observational and may not be generalizable to other healthcare settings. Further study is necessary to understand differences in outcomes and the financial impact of VHH monitoring compared to observation hospitalizations for COVID-19 patients with similar risk profiles.

**Acknowledgments.** The authors would like to thank all of the Virtual Hospital at Home staff for their dedication to outstanding patient care.

Financial support. No financial support was provided relevant to this article.

**Conflicts of interest.** All authors report no conflicts of interest relevant to this article.

#### References

- Garg S, Kim L, Whitaker M, *et al.* Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019– COVID-Net, 14 states, March 1–30, 2020. *Morb Mortal Wkly Rep* 2020;69:458–464.
- Webb Hooper M, Napoles AM, Perez-Stable EJ. COVID-19 and racial/ethnic disparities. JAMA 2020;323:2466–2467.
- Singh GK, Lin CC. Area deprivation and inequalities in health and health care outcomes. *Ann Intern Med* 2019. doi: 10.7326/M19-1510.
- Levine DM, Ouchi K, Blanchfield B, et al. Hospital-level care at home for acutely ill adults: a pilot randomized controlled trial. J Gen Intern Med 2018;33:729–736.
- Shepperd S, Iliffe S, Doll HA, et al. Admission avoidance hospital at home. Cochrane Database Syst Rev 2016;9:CD007491.